Quantcast

Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.

Research paper by J M JM Conil, B B Georges, A A Breden, C C Segonds, M M Lavit, T T Seguin, N N Coley, K K Samii, G G Chabanon, G G Houin, S S Saivin

Indexed on: 16 Aug '06Published on: 16 Aug '06Published in: International Journal of Antimicrobial Agents



Abstract

Altered pharmacokinetics in burn patients may affect antibiotic plasma concentrations. Typical once-daily dosing (ODD) of 15 mg/kg amikacin (AMK) in burn patients does not always produce peak concentrations (C(max)) reaching the therapeutic objective of six to eight times the minimal inhibitory concentration (MIC). We recorded plasma concentrations following administration of 20 mg/kg AMK in burn patients and studied factors affecting pharmacokinetics. Mean C(max) was 48.3+/-10.8 mg/L and the C(max)/MIC ratio was 6+/-1.35. Statistical analysis demonstrated a relationship between C(max) and the area of the burn and Unit Burn Standard, and between AMK clearance and creatinine clearance (Cl(CR)). We conclude that ODD regimens of AMK in patients with burns >15% body surface area and/or with Cl(CR) >120 mL/min could require doses >20 mg/kg to reach adequate C(max). In all cases, patient therapeutic drug monitoring is essential to ensure the safe usage of these dosing recommendations.